| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10.7% | 0% | $324M | 3.37M | 0% | RA Capital Management, L.P. | Nov 13, 2025 | |
| BCLS Fund III Investments, LP | 9.99% | 0% | $289M | $49.8M | 3.02M | +20.8% | BCLS Fund III Investments, LP | Sep 30, 2025 |
| Point72 Asset Management, L.P. | 6.2% | -17.5% | $151M | $4.8M | 1.58M | +3.28% | Point72 Asset Management, L.P. | Sep 30, 2025 |
| BIOTECHNOLOGY VALUE FUND L P | 4.4% | -16% | $114M | -$21.5M | 1.19M | -15.9% | BVF PARTNERS L P/IL | Oct 15, 2025 |
| Vivo Opportunity Fund Holdings, L.P. | 4.6% | -2% | $57.3M | $27.4M | 1.18M | +92% | Vivo Opportunity Fund Holdings, L.P. | Jun 30, 2025 |
| BlackRock, Inc. | 4.6% | -15% | $111M | $5.36M | 1.16M | +5.05% | BlackRock, Inc. | Sep 30, 2025 |
| Adage Capital Management, L.P. | 4.97% | -45.2% | $53.6M | $5.36M | 1.1M | +11.1% | Adage Capital Management, L.P. | Jun 30, 2025 |
| Paradigm Biocapital Advisors LP | 3.3% | -38.3% | $92M | -$16M | 961K | -14.8% | Paradigm BioCapital Advisors LP | Sep 30, 2025 |
| Venrock Healthcare Capital Partners III, L.P. | 3.2% | -67% | $42.8M | -$30.8M | 639K | -41.8% | Venrock Healthcare Capital Partners III, L.P. | Jun 30, 2025 |
| Commodore Capital LP | 2% | -58.3% | $56M | -$56.5M | 585K | -50.2% | Commodore Capital LP | Sep 30, 2025 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Change | Price | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 32.5M | $3.11B | +$680M | $95.76 | 165 |
| 2025 Q2 | 25.9M | $1.26B | +$803M | $48.71 | 106 |
| 2025 Q1 | 9.56M | $206M | +$57.6M | $21.54 | 45 |
| 2024 Q4 | 6.87M | $184M | +$101M | $26.88 | 40 |
| 2024 Q3 | 3.31M | $35.6M | +$20.4M | $10.75 | 27 |
| 2024 Q2 | 1.41M | $16.9M | +$16.9M | $11.94 | 25 |